Under our management philosophy of “the Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies”, we continuously work on research and development to discover new drugs for addressing unmet medical needs by taking advantage of the state-of-the-art biotechnologies in the four key areas of oncology, nephrology, immunology/allergy, and Neurology.
As a Japan-based R&D life science company centered in biopharmaceuticals, Kyowa Kirin has been focused on in-house pharmaceutical R&D and manufacturing and also for over 30 years, we have been engaging in open innovation collaboration with academia. All of our efforts above have led to the birth of 3 Kyowa Kirin antibody pharmaceuticals which are now available for patients globally. We will continue to develop revolutionary new drugs by organically connecting expertise and know-how inside as well as outside the company.
So far, we have achieved one of our goals in our current Mid-Term Business Plan to deliver new drugs under the Kyowa Kirin brand to patients in a global scale including Europe and the U.S., and those drugs are becoming available for more and more markets. It’s wonderful that the Kyowa Kirin new drugs provide new values to the patients, followed by their joy. I truly believe that Kyowa Kirin has been steadily growing into one of the few companies in the world that own its distinctive value.
Combining individual strength of all our employees, we will continue to contribute to the health and well-being of people around the world. We look forward to your ongoing support in our endeavors.
Executive Director of the Board
President and Chief Executive Officer
Masashi Miyamoto
